argenx SE

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 05 feb 2016 - 07:00

Statutaire naam argenx SE

Titel argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference

Bericht Breda, the Netherlands / Ghent, Belgium, 5 February 2016- argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City (NY, USA) on Thursday, February 11, 2016 at 1:50pm ET.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201602050000000001_Press release (PDF).pdf (opens in a new window)

Datum laatste update: 16 december 2025